Focus on research reproducibility
The pharmaceutical industry is facing an increasing number of productivity challenges. From 2010-18, the cost of bringing a new drug to market almost doubled, to $2.2bn, whilst the average project length increased from 9.7 years in the 1990s to 10-15 years in the 2010s. Avoidable Experiment Expenditure (AEE) is a significant source of unnecessary spend and effort, significantly contributing to the increase in project costs and length. Over 40% of spend on drug development goes toward preclinical R&D, however, irreproducibility rates in preclinical experiments exceed 50%, costing the industry nearly $48 billion annually. Over a third of this, or more than $17 billion, can be attributed to the ineffectiveness of biological reagents or reference materials.
Addressing reagent related AEE through the provision of high-quality reagents will allow life science organisations to recoup unnecessary spend whilst improving R&D efficiency, bringing drugs to clinical trial faster, and generally accelerating pipeline progress